---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263491"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:35:40.807844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials

## Summary
- Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.
- Collaboration revenue of $20.8M from Kyowa Kirin partnership; no revenue in prior year.
- Pro forma cash $609.7M; cash runway into 2027 supports ziftomenib program through KOMET-017 topline.
- First patients dosed in KOMET-017 Phase 3 (frontline AML) and FLT3 inhibitor cohort of KOMET-007.
- PDUFA target date Nov 30, 2025 for ziftomenib in R/R NPM1-m AML; two oral ASH 2025 abstracts.

## SEC filing metadata
- accession: 0001193125-25-263491
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/0001193125-25-263491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263491
- JSON: https://secwatch.observer/filing/0001193125-25-263491.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.